Walleye Capital LLC Reduces Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA)

Walleye Capital LLC reduced its holdings in shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 72.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 110,988 shares of the company's stock after selling 290,994 shares during the quarter. Walleye Capital LLC owned approximately 0.23% of Cabaletta Bio worth $252,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in CABA. LPL Financial LLC lifted its holdings in Cabaletta Bio by 15.6% in the 4th quarter. LPL Financial LLC now owns 42,386 shares of the company's stock valued at $96,000 after purchasing an additional 5,716 shares in the last quarter. Intech Investment Management LLC lifted its stake in shares of Cabaletta Bio by 42.2% during the fourth quarter. Intech Investment Management LLC now owns 20,203 shares of the company's stock valued at $46,000 after buying an additional 5,999 shares during the period. SG Americas Securities LLC boosted its position in Cabaletta Bio by 23.3% during the fourth quarter. SG Americas Securities LLC now owns 43,259 shares of the company's stock worth $98,000 after acquiring an additional 8,161 shares during the last quarter. Barclays PLC grew its stake in Cabaletta Bio by 17.2% in the 4th quarter. Barclays PLC now owns 71,617 shares of the company's stock worth $163,000 after acquiring an additional 10,487 shares during the period. Finally, Miller Financial Services LLC acquired a new position in Cabaletta Bio in the 4th quarter valued at $33,000.

Cabaletta Bio Stock Performance

Shares of NASDAQ:CABA traded down $0.04 during midday trading on Thursday, hitting $1.29. 107,228 shares of the company's stock traded hands, compared to its average volume of 1,444,547. Cabaletta Bio, Inc. has a twelve month low of $0.99 and a twelve month high of $13.50. The company has a market cap of $65.20 million, a PE ratio of -0.60 and a beta of 2.44. The firm's fifty day moving average price is $1.48 and its two-hundred day moving average price is $2.47.

Cabaletta Bio (NASDAQ:CABA - Get Free Report) last issued its quarterly earnings data on Monday, March 31st. The company reported ($0.65) EPS for the quarter, hitting analysts' consensus estimates of ($0.65). As a group, equities research analysts anticipate that Cabaletta Bio, Inc. will post -2.34 EPS for the current fiscal year.

Wall Street Analyst Weigh In

CABA has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $25.00 price objective on shares of Cabaletta Bio in a research report on Tuesday, April 1st. Wells Fargo & Company lowered their price target on Cabaletta Bio from $6.00 to $3.00 and set an "equal weight" rating for the company in a report on Tuesday, April 1st. UBS Group cut their price objective on shares of Cabaletta Bio from $10.00 to $7.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Morgan Stanley dropped their price target on shares of Cabaletta Bio from $30.00 to $22.00 and set an "overweight" rating for the company in a research report on Tuesday, April 1st. Finally, Guggenheim reiterated a "buy" rating and issued a $23.00 price target on shares of Cabaletta Bio in a report on Tuesday, April 1st. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $21.00.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.